Cencora Patient Support Services (Lash Group)

Overview

Cencora’s Patient Support Services division — historically branded as Lash Group — is one of the founding hub services providers in the United States, operating continuously since 1986. The division has served more than 18 million patients across 20+ therapeutic areas, operates 100+ patient support programs, and employs approximately 4,000 people from its Fort Mill, South Carolina headquarters.

The parent company, Cencora (NYSE: COR, formerly AmerisourceBergen), is one of the “Big 3” U.S. pharmaceutical distributors with $321.3 billion in FY2025 revenue. The Lash Group represents a small fraction of total revenue (~$845M estimated) but carries strategic value as a high-touch, higher-margin service layer.

Critical development (November 2025): CEO Robert Mauch classified legacy US hub services as non-core, moving them to the “Other” reporting segment for potential divestiture or partnership. This creates a significant M&A catalyst for the hub services landscape. Cencora is pivoting toward specialty physician networks ($10B+ in physician-focused acquisitions since January 2025: RCA for $4.4B, OneOncology for $5B, EyeSouth for $1.1B) while positioning hub services for exit. (Source: raw/cencora-lash-group-profile.md)

Services & Capabilities

Full-Stack Hub Services

• Program Enrollment — Patient intake, eligibility screening, onboarding
• Benefit Verification — AI-driven electronic BV with “Eva” digital assistant for automated payer calls
• Prior Authorization — Heavily staffed PA support; ePA integrated into EHRs (Epic); 38% PA reduction and 28 min savings per PA reported
• Appeals Management — End-to-end appeals handling for denied claims
• Financial Assistance — Copay card management, PAP enrollment, foundation/charity grants, 340B coordination
• Pharmacy Coordination — Direct integration with Cencora’s distribution network and specialty pharmacy partners
• Adherence Programs — Predictive analytics-driven coaching; Medisafe digital app partnership; nurse-led outreach
• Nurse Support — RNs for injection training, patient education, home care, clinical support
• Field Reimbursement — Field teams at hospitals/clinics for billing, eligibility, and payer policy navigation
• Free Goods Dispensing (TheraCom) — Licensed in all 50 states; 100+ free goods programs; 1M+ Rx dispensed annually; 25+ disease states

Call Center Operations

• ~4,000+ employees in patient services division
• Primary location: Fort Mill, SC (1,200+ at HQ in 247,834 sq ft facility)
• Program-specific “concierge” teams with nurses, field reps, and call center agents

Competitive Position

Key Differentiators

1. Distribution network integration — Only hub with direct, real-time visibility into the pharmaceutical supply chain via parent’s distribution network. No independent hub can replicate this.
2. Scale and experience — 30+ years, 18M+ patients, 100+ programs. Deepest institutional knowledge across therapeutic areas.
3. Clinical infrastructure — High-touch model with trained nurses, injection trainers, and field reimbursement teams suited for complex therapies (cell/gene, oncology, rare disease).
4. Integrated dispensing (TheraCom) — 50-state-licensed specialty pharmacy handles free goods/PAP in-house, eliminating hand-off failure points.

Key Weaknesses

1. Non-core strategic classification — Clients may hesitate to award new programs during ownership uncertainty; talent retention risk.
2. Technology lag — Despite investments in Eva and Fusion, trails CareMetx, AssistRx, and PHIL on automation, self-service, and API connectivity.
3. Conflict of interest — As a distributor-owned hub, manufacturers worry about channel steering toward Cencora’s distribution network.
4. Disclosure opacity — Rarely publishes performance metrics; disadvantaged in RFP evaluations vs. independents that share time-to-therapy and adherence lift data.
5. Brand fragmentation — Lash Group, TheraCom, Cencora Patient Support, Benefit eServices create market confusion.

Competitive Comparisons

• vs. ConnectiveRx: Cencora wins on scale and clinical depth for complex therapies; loses on pricing flexibility, customer satisfaction, and nimbleness for smaller programs.
• vs. Eversana: Cencora wins on pure hub scale and distribution integration; loses to Eversana’s full commercialization model (sales + marketing + hub) with success-share pricing.
• vs. AssistRx: Cencora wins on scale, breadth of clinical support, complex therapy management; loses on speed, digital nativeness, and prescriber workflow integration.

Estimated Market Position

• US hub services market estimated at ~$1.6-1.7B (2024-2025)
• Lash Group estimated at ~$845M revenue = ~25-30% market share (inflated by TheraCom distribution revenue)
• Tier 1 provider alongside Eversana, McKesson/CoverMyMeds, and Valeris

Recent Developments

Date	Development
Aug 2023	AmerisourceBergen rebrands to Cencora; Lash Group subsumed under new corporate identity
Oct 2024	CEO succession: Robert Mauch replaces Steven Collis
Jan 2025	Retina Consultants of America (RCA) acquired for $4.4B
Nov 2025	Legacy US hub services classified as non-core — moved to “Other” segment; strategic alternatives explored
Nov 2025	$1B distribution network investment through 2030
Dec 2025	OneOncology acquisition announced for $5B
Feb 2026	MWI Animal Health divested to Covetrus for $3.5B
Feb 2026	New segment reporting: US Healthcare Solutions, International Healthcare Solutions, Other
Mar 2026	CFO James Cleary announces retirement effective June 2026
Mar 2026	EyeSouth Partners retina business acquired for $1.1B

Client & Partner Ecosystem

Target Customers

• Large pharma with complex, high-touch specialty therapies (cell/gene, oncology, rare disease)
• Manufacturers already using Cencora for distribution seeking a single-vendor solution
• Programs requiring integrated free goods dispensing and field reimbursement

Known Partnerships

• TrakCel — Integrated cell & gene therapy orchestration (OCELLOS + Fusion platform)
• Medisafe — Digital adherence app partnership
• AllazoHealth — AI-driven predictive adherence pilot (>90% patient engagement in 2021 pilot)
• Specific manufacturer clients undisclosed; long-standing relationships in oncology, vaccines, and biologics

Who Should NOT Use Cencora

• Emerging biotechs needing speed and digital-first tools (consider AssistRx or CareMetx)
• Manufacturers with exclusive distribution through McKesson or Cardinal Health (conflict of interest)
• Programs prioritizing digital patient experience (PHIL or CareMetx)
• Companies seeking full commercialization partner (consider Eversana)

Technology Platform

• Fusion — CRM and patient support ecosystem leveraging AI/ML for BV, PA, and multi-channel communication
• Eva (Electronic Verification Assistant) — AI digital assistant making automated payer calls for BV using conversational AI
• Cencora Benefit eServices — Suite including Eligibility Verification, Real-Time Prescription Benefit (RTPB), and ePA integrated into Epic and other EHRs; KLAS Points of Light recognition
• TrakCel/OCELLOS Integration — Cell and gene therapy orchestration platform for real-time patient journey visibility

Therapeutic Focus

Oncology, cell and gene therapy, rare disease, autoimmune/inflammatory, ophthalmology (via RCA adjacency), vaccines, and complex biologics requiring injection training. Strength in the highest-acuity therapies where clinical support depth matters most.

Target Customers

Large pharma manufacturers with multi-brand portfolios, complex specialty therapies requiring clinical depth, and programs needing deep payer navigation and free goods dispensing. Mid-size biotechs more likely to choose nimbler competitors unless the therapy demands Lash Group’s clinical infrastructure.

Sources

• Raw profile: cencora-lash-group-profile.md
• CB Insights: Lash Group
• IntuitionLabs: Patient Hub Platform Comparison
• Cencora Patient Access & Adherence
• Cencora FY2025 Earnings (Nasdaq)
• BioXconomy: Non-core classification
• SEC Filing: Segment restructuring